Spis treści:
4. PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ
| KOMISJA NADZORU FINANSOWEGO | ||||||||||||
| Raport bieżący nr | 5 | / | 2017 | |||||||||
| Data sporządzenia: | 2017-04-03 | |||||||||||
| Skrócona nazwa emitenta | ||||||||||||
| MILESTONE MEDICAL | ||||||||||||
| Temat | ||||||||||||
| Regulatory Marketing Clearance to Sell Epidural and Intra-Articular Instruments and Disposables in Australia | ||||||||||||
| Podstawa prawna | ||||||||||||
| Art. 17 ust. 1 MAR - informacje poufne. | ||||||||||||
| Treść raportu: | ||||||||||||
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, "the Company", "the Issuer"), today announced that it has been granted marketing clearance for its epidural and intra-articular instruments and disposables in Australia. Dynamic Pressure Sensing® (DPS) capability in the CompuFlo® Epidural instrument provides feedback that allows anesthesiologists to correctly identify the epidural space, which has the potential to significantly reduce complications and malpractice compared to conventional techniques. DPS technology is also incorporated into the CompuFlo® Intra-Articular instrument to provide precise computerized drug injections into intra-articular joint spaces in osteoarthritis patients. CompuFlo® Intra-Articular provides drug delivery accuracy, reduces patient discomfort and prevents needle deflection. The Board of Directors of Issuer is pleased to announce regulatory marketing clearance to sell its epidural and intra-articular instruments and disposables in Australia. Australia represents a sizable market for its technology with more than 300,000 live births per year and approximately 1.8 million residents with osteoarthritis. The CompuFlo® Epidural and Intra-Articular instruments provide new clinical tools to enhance the safety and reduce pain associated with epidural and intra-articular procedures. |
||||||||||||
| MESSAGE (ENGLISH VERSION) | |||
INFORMACJE O PODMIOCIE >>>
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |||||
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | ||
| 2017-04-03 | Joseph D'Agostino | Chief Financial Officer | Joseph D'Agostino | ||
Źródło:Komunikaty spółek (ESPI)
